← Return to all swing-trade opportunities
MEDP — 20-Day Breakout with Volume
Status: Invalidated
Scanner score: 55.0/100
Why this was flagged
MEDP was identified as a bullish technical setup based on the 20-Day Breakout with Volume pattern. The scanner found a score of 55.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
The scanner found Medpace Holdings Inc (MEDP) because it is following a pattern called a 20-Day Breakout with Volume. This means the price moved above the highest point it reached in the last 20 days. This move happened with high volume, which means more shares were traded than usual. The Relative Strength Index (RSI), a tool used to measure how fast prices are moving, shows healthy momentum without being too high.
What the price plan means
The entry zone is between $605.82 and $612.53. If you enter here, there are two target prices: $686.29 and $726.52. The reward-to-risk ratio is 2, which compares the potential profit to the potential loss. To manage risk, a stop-loss price of $565.59 is set. A stop-loss is a price level where an investor might exit to prevent further losses if the price drops.
What could make the idea fail
The setup could fail if the price falls below the stop-loss level of $565.59. This would mean the technical pattern did not work as expected.
Important reminder
This information is based on technical patterns and mathematical rules. It is not a prediction of future results. Always do your own research before making any financial decisions.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Caution (High confidence)
Medpace Holdings Inc. reported strong Q2 2026 results, beating consensus estimates for both EPS ($4.25) and revenue ($707.33 million). The company raised its full-year 2026 guidance and maintains a robust project backlog exceeding $3 billion. However, there is significant divergence in market sentiment. While recent earnings performance was strong, analysts have expressed valuation concerns, leading to downgrades from some firms. Furthermore, the average 12-month price target of $490.36 suggests potential downside relative to current trading levels, and an SEC filing indicates a proposed sale of 11,000 shares.
Potentially supportive context
- Q2 2026 earnings and revenue exceeded analyst expectations.
- Full-year 2026 guidance was raised following strong performance.
- Project backlog grew to over $3.01 billion with $795.7 million in net new business awards.
Risks and caution items
- Analysts have issued downgrades due to valuation concerns.
- The average 12-month price target of $490.36 implies potential downside from current levels.
- An SEC filing indicates a proposed sale of 11,000 shares of common stock.
- Consensus analyst rating remains a 'Hold' with significant variation in individual forecasts.
Latest reviewed article: Jul 23, 2026 8:10 pm
Recent related articles
Medpace Holdings, Inc. (MEDP) filed a Form 144 SEC notice on July 23, 2026, indicating a proposed sale of 11,000 shares of common stock with an aggregate market value of $6,950,877.79. The securities were acquired through a stock option exercise on December…
Medpace Holdings Inc. (MEDP) saw its stock jump 14.71% after reporting strong Q2 2026 results, beating Street expectations for EPS and revenue, and raising its full-year 2026 guidance. Despite recent downgrades from Baird and Jefferies due to valuation concerns, Mizuho maintained an…
Medpace Holdings (NASDAQ:MEDP) reported strong Q2 earnings, beating consensus estimates with $4.25 EPS and $707.33 million in sales. The company's project backlog grew to over $3.01 billion, with net new business awards totaling $795.7 million. Following these results, Medpace raised its fiscal…
Medpace Holdings, Inc. (MEDP) published its Q2 2026 earnings call presentation, reporting strong financial results. The company's EPS of $4.25 beat estimates by $0.25, and revenue of $707.33M represented a 17.24% year-over-year increase, surpassing expectations by $18.52M. This article provides access to…
Analysts have raised the average 12-month price target for Medpace Holdings, Inc. (MEDP) stock to $490.36, up from $485.36, with individual forecasts ranging from $400 to $586. This updated target suggests a potential 7% downside based on the July 22 closing price.…
Medpace Holdings, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing by 17.2% to $707.3 million and net income rising to $121.4 million. The company also reported a significant increase in net new business awards, totaling $795.7…
Medpace (MEDP) reported a strong Q3 2025 with revenue up 23.7% to $659.9 million, net income increasing by 15.3%, and robust net new business awards rising 47.9%. The company's backlog reached $3.0 billion, and it provided optimistic guidance for 2025 revenue and…
This article provides the latest stock information for Medpace Holdings Inc (MEDP), including its pre-market price, market capitalization, and key financial metrics. It also highlights recent news, such as Medpace beating Q2 earnings and revenue estimates, and identifies it as a top…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Current volume is at least 1.25x the 20-day average volume.
- RSI is in a constructive momentum range without being overbought.
- Price closed above the prior 20-day high with above-average volume.